The inhibition of P-glucuronidase by mam ng animals maintained on normal diets in metabolism cages. steroids, from the fl-D-glucosiduronic acid con-The rat and guinea-pig exereta were separated by filtration, jugates. P-Glucuronidase assay is normally con-and the faeces washed with water, before the combined ducted with a chromogenic substrate, the enzymic urine and washings were tested. Urines were stored at 0' if hydrolysis of which may be diminished in the examined within 24 hr. of collection, or otherwise at -20°. glucuronidase, however, mammnalian urine con-for 40 min. after adjustment with 3N-HCl to pH 2-0-2-2, tains trueenzymeinhibitrs Abul-Fadl(1957) followed by readjustment with NaOH to pH 4-0-45, or tamns true enzyme inhibitors. Abul-Fadl (1957) (b) at 100°for 15 min. after adjustment with 0-1 N-NaOH to found both dialysable and non-dialysable material pH 7-5-8-0, follQwed by readjustment with HCI to pH 60-in human urine which was inhibitory to /-gluc-6-5. The inhibitory power was maximal after treatment
1958). Thus the most powerful inhibitors of p. then discarded, The supernatant was diluted for assay to a glucuronidase, for which the only known sub-final volume of 200 ml./g. of moist liver, Biosynthetic strates are -D-glucosiduronic acids and -D-phenolphthalein ,B-D-glucuronide (Levvy & Marsh, 1959) , concn. 0-63 mM, was the standard substrate for the enzyme galactosiduronic acids , are assay, which was for 1hr. at 37°in 0125a-acetic acid-D-glucaro-(1-+4)-lactone and the unidentified lac-NaOH buffer, pH5-2, as described by Levvy & Marsh tones in boiled mucic (galactaric) acid solution (1959) . The incubation mixture (4 ml.) included 0-5 ml. of (Levvy, 1952) . A further examination of the enzyme solution, which liberated 35A40,ug. of phenol. dialysable material in urine indicated the presence phthalein in assays not containing urine or other solutions of a compound with properties consistent with inhibitory to the enzyme. The assay did not require the those of forming a lactone inhibitory to P-gluc-presence of an 'activator', as is essential when /-glucuronuronidase, and an attempt was therefore made to idase preparations of higher specific activity are used (Bernfeld, Bernfeld, Nisselbaum & Fishman, 1954;  Levvy, isolate and identify it.
McAllan . For the determination of their A preliminary account of some of this work has . . . been published Marsh, 1961). ihibitory power, treated urine samples were added in been published (Marsh, 1961) . known concentration to the buffered substrate immediately before the final addition of the enzyme, and the assay was METHODS AND MATERIALS carried out as before. Extra controls were included to compensate for the inherent colour of the urine. All assays Urine samples. Human pregnancy urine in bulk and were performed in duplicate. samples of normal human 24 hr. urines (male and female)
Other glycoidase assays. Assays of ca-mannosidase, ,B.
were obtained from the M.R,C, Obstetric Medicine galactosidase and P-N-acetylglucosaminidase, with p. 77 7(. A. MARSH nitrophenyl a-D-mannoside, o-nitrophenyl ,B-D-galactoside and p-nitrophenyl N-acetyl-,B-D-glucosaminide as the respective substrates, were as described by Conchie, Findlay & Levvy (1959) , with a partially purified ratepididymis preparation as the common enzyme source. Uronic acid determination. Total uronic acid in urine samples was measured by a modification of the carbazole method of Dische (Ashwell, 1957) , and colour intensity was measured on the Spekker photoelectric absorptiometer with Ilford no. 605 yellow-green filters (peak transmission 545 m). The addition of D-glucuronic acid gave recoveries of 90-95 %. The extinction coefficient given by free D-galacturonic acid in this method was 80 % of that given by D-glucuronic acid.
Paper chromatography. The spots given by sugar acids after descending paper chromatography on Whatman no. 1 paper were developed by the aqueous acetone-silver nitrate method of Trevelyan, Procter & Harrison (1950) , and fixed with 5% (w/v) sodium thiosulphate (Hulme, 1961 ,-glucuronidase, and the supernatant after sedimentation of denatured protein was found to inhibit P-glucuronidase. The inhibitory power of the urine was considerably increased on further boiling after acidification. Thus, in a typical experiment, 25 % (v/v) normal male-human urine caused 74 % inhibition of rat-liver ,B-glucuronidase after the urine had undergone standard acid treatment at pH 2-0-2-2 (see the Methods and Materials section), but caused only 43 % inhibition after alkali treatment of the urine at pH 7-5-8-0. When preparations were treated thus and added to the enzyme assay in equal final concentration, the inhibitory effects with crude urine were identical with those of both the diffusate and of the residue after dialysis of the urine for 3 days at 00 against an equal volume of water. The residue freed from all dialysable material was non-inhibitory after boiling at acid or alkaline pH. Thus the factors in boiled urine inhibitory to f-glucuronidase were dialysable, and in subsequent experiments only crude urine samples were employed, unless otherwise stated.
Reversibility of the acid treatment. The high inhibitory power of the urine after acid treatment was decreased by subsequent treatment at pH 75-8-0, and then re-established by a second acid treatment. Similar results were obtained by initially treating the urine with alkali and then subjecting it to alternate acid and alkali treatments (Table 1) . Acid treatment therefore converted an entity normally present in urine into a more powerful inhibitor of ,B-glucuronidase, which was again transformed by alkali, presumably to the original compound. Pregnancy urine gave similar results but was more inhibitory after acid treatment.
Effect of extraction with ethyl acetate. Boiled urine, which, when present in 25 % (v/v) concentration in the fi-glucuronidase assay, caused 69 and 45 % inhibition of the enzyme after acid and alkali treatments respectively, was extracted for 2 hr. with ethyl acetate (analytical reagent) in a continuous liquid-liquid micro-extractor (Levvy, 1948) . The aqueous residue then displayed greater acid potentiation of enzyme inhibition (57 % inhibition after acid treatment, 22 % inhibition after alkali treatment, at a urine concentration of 25 % in the assay). The residue after evaporation of the ethyl acetate extract was, however, equally inhibitory (34 % inhibition at a urine concentration of 25 %) after acid or alkali treatment.
It would thus seem that there is a dialysable entity present in urine which after alkali treatment has considerably less inhibitory activity towards f-glucuronidase, but which acid treatment converts reversibly into a potent inhibitor. Inhibition after acid or alkali treatments is augmented by the presence of other material, including probably glucosiduronic acids of endogenous origin, soluble in ethyl acetate at pH 2. Specificity of inhibition. Urine boiled at acid and alkaline pH was tested as an inhibitor of the mammalian glycosidases fi-galactosidase, a-mannosidase and fi-N-acetylglucosamninidase (Table 2) . (Human pregnancy urine was employed here since it displayed greater inhibitory activity to pglucuronidase than normal urine after acid treatment.) There was negligible inhibition of these enzymes at concentrations of urine giving appreciable inhibition of P-glucuronidase. The inhibitory factors present in the urine were thus specific for fl-glucuronidase.
Increa8e of inhibitory power at pH of a88ay. Development of inhibitory activity of urine also occurred at the pH and temperature of normal pglucuronidase assay but less rapidly than at pH 2 and 1000. Fig. 1 shows the effect of preincubating pregnancy urine, previously boiled at pH 7 5, for various periods at pH 45, 5-2 and 6-1, when included at 10% (v/v) concentration in the assay of the ratliver enzyme for 1 hr. Without prior incubation the percentage inhibition by urine was greater at pH 4 5 than at pH 5-2 or 6 1; f-glucuronidase activity at pH 6 1 was less than 50 % of the optimum. On incubation before the assay, the inhibition by urine increased appreciably at pH 4-5 or 5-2, but remained constant at pH 6-1, owing to non-conversion into the acid-potentiated inhibitor. The results with normal female urine were similar, but the increase in inhibitory power was less marked since there was a smaller amount of acid-potentiated inhibitor present initially.
Effect of addition of ascorbic acid. Mammalian P-glucuronidase is strongly inhibited by heavymetal ions, and inhibition by Cu2+ ion is greatly potentiated by the presence of L-ascorbate, presumably owing to formation of the inactivating Cu+ ion (Levvy & Marsh, 1957a; Fernley, 1962) . In order to eliminate the possibility that the inhibition of acidified urine was partly due to the combination of ascorbic acid and traces of copper (see Levvy & Marsh, 1959) . the addition of 1 mM-L- ascorbate to the urine was examined. No effect on the inhibitory powers of the urine after acid or alkali treatment was noted, and the potentiation of the inhibition by acid was fully reversible as before.
Variation of inhibitor and sub8trate concentration. The inhibition on varying the concentration of the acid-and alkali-treated urine is shown in Fig. 2 ; to achieve concentrations up to 100 % the urine was initially concentrated to 50 % of the original volume under reduced pressure at 45°. At high urine conVol. 86 79
-----B centrations, more than 90 % inhibition of the enzyme could be achieved, but error due to interference by the inherent urine colour in the assay then became appreciable. Examination, by the graphical method of Lineweaver & Burk (1934) , of the inhibitions at fixed urine and variable substrate concentrations showed that the inhibitory factors in both acid-and alkalitreated urine acted competitively.
Measurement of the acid-potentiated inhibitor in urine To provide a basis for the comparison of excretion rates of the acid-potentiated inhibitor in urine under different conditions, an arbitrary unit was, selected, namely 1 'unit of inhibitor' (u.i.), which was defined as that quantity which produced 50 % inhibition of rat-liver P-glucuronidase in the standard assay at pH 5-2 with 0-63 mM-phenolphthalein f-glucuronide as substrate. From the graph (Fig. 2 ) of inhibition against concentration of acid-treated urine, the u.i. present in a urine specimen could be measured. Correction was made for the augmentation of inhibition due to the alkali-stable factor, this being measured in u.i. from the same curve. parallel. Thus the inhibitory power (in u.i.) of the alkali-treated urine was subtracted from that of the acid-treated urine at the same concentration, to provide a measure of the acid-potentiated inhibitor present. This method of measurement was justifiable subject to the following assumptions: (a) the inhibitory power of the other substances present in the alkali-treated urine was independent of pH; (b) the entity which displayed inhibitory activity after acid treatment was virtually noninhibitory at the same concentration after alkali treatment; (c) inhibitions by this entity and the other inhibitory substances were entirely additive.
Substantiation of these assumptions could only be made by complete separation of the acidpotentiated inhibitor from other inhibitory compounds in the urine. However, the removal by ethyl acetate of a fraction equally inhibitory after acid and alkali treatment to leave a residue with more pronounced acid-potentiated inhibition, and the pronounced-increase in excretion of acidpotentiated inhibitor after ingestion of D-glucuronolactone (see below), -suggested their validity.
aompari8on of urines of different mammalian speciem. An acid-potentiated ,B-glucuronidase inhibitor, having the same properties as that in human urine, was found in the urines of all other mammalian species tested (Table 3) . There was considerable variation in its concentration between individuals of the same species. Estimation of the daily excretion in man, rat and guinea pig was made by the collection of 24 hr. urine samples. The excretion by normal human subjects was fairly constant, being somewhat higher in males than in females.
Influence of inge8tion of D-glucuronolactone. Freshly prepared aqueous solutions of D-glucuronolactone given orally elevated greatly the excretion of the acid-potentiated inhibitor within 24 hr. of ingestion (Table 4) . With human subjects a single dose of 5 g. of D-glucuronolactone was given, whereas in the rat and guinea pig the dose was repeated over consecutive days. D-Glucuronolactone is a relatively innocuous compound when ingested; Deichmann & Hopfenspirger (1951) state the lethal dose for rats to be 20 g./kg. body wt. after oral administration,
The increase of excretion of the inhibitor in man was 100-fold in the 24 hr. after ingestion of Dglucuronolactone, returning to a normal value after 48 hr. The corresponding increases in the excretion of inhibitor in the guinea pig and rat, given proportionally higher oral doses than the human subject, were 500-and 10-fold respectively during the 24 hr. after the first dose, and were maintained by further doses of D-glucuronolactone. The increased excretion by man of total uronic acid, measured as D-glucuronic acid, within 24 hr. Isolation and identification of the acid-potentiated fi-glucuronidase inhibitor in human urine
The general properties of the acid-potentiated inhibitor in mammalian urine suggested the presence of a sugar acid readily convertible by acid into an inhibitory lactone, and the specific nature of the inhibition for ,-glucuronidase led to the belief that the inhibitory entity might be a lactone of D-glucaric acid or galactaric acid, these being the most potent inhibitors of mammalian ,-glucuronidase. The great increase in the excretion of the inhibitor after ingestion of D-glucuronolactone supported this assumption; oxidation of the C-1 reducing group of D-glucuronolactone would lead directly to the formation of D-glucaric acid, whereas inversion at C-4 would also be required to produce galactaric acid. D-Glucaric acid boiled at an acid pH is converted in 30 % yield into D-glucaro-( 1-4)-lactone, the specific ,-glucuronidase inhibitor (Levvy, 1952) . When tested, addition of 24 1,um-moles (5.06,ug.) of boiled Dglucaric acid to the assay gave 50 % inhibition of rat-liver P-glucuronidase; this quantity was thus equivalent in inhibitory power to 1 unit of the acidpotentiated urine inhibitor. The excretion of 180 000 units of the inhibitor within 24 hr. of a dose of 28 m-moles (5 g.) of D-glucuronolactone (Table 4) was thus equivalent to 4-34 m-moles of boiled D-glucaric acid, i.e. 16 % of the dose. Since the inhibitory power of boiled galactaric acid is only 2 % that of boiled D-glucaric acid (Levvy, 1952) , conversion into galactaric acid could not account for the high inhibitory power of acidtreated urine after ingestion of D-glucuronolactone.
Isoltion of D-glucaric acid from pregnancy urine. The acid-potentiated urine inhibitor in human pregnancy urine was concentrated by the procedure given in Scheme 1. This included the partial removal of less soluble inorganic salts etc., removal of endogenous glucuronides by extraction with ethyl acetate after acidification, and precipitation of the inhibitor as a lead salt which was then decomposed with H2S. The final product consisted of a yellow syrupy aqueous solution containing the inhibitor as an ammonium salt; its inhibitor content (in Iu.i.) was equivalent to 294 mg. of Dglucarate. This solution (65 ml.) was heated with 10 g. of phenylhydrazine hydrochloride and 2-5 g. of anhydrous sodium acetate for 5 min. at 1000, and the tarry material formed was removed by decantation of the hot mixture. A further 5 g. of phenylhydrazine hydrochloride was added to the aqueous residue, and the mixture heated for a further 150 min. at 1000. When cooled overnight at 00, it deposited a yellowish crystalline solid (0.31 g.), which after recrystallization from aq. 50% (v/v) Isolation of D-glucaric acid from urine after ingestion of D-glucuronolactone. The same product was isolated, by a similar but simpler procedure to that outlined above, from male human urine excreted within 24 hr. of a 5 g. oral dose of D-glucuronolactone. The urine (1890 ml. containing 150 000 u.I.) was concentrated under reduced pressure to 800 ml. and boiled for 15 min. The supernatant (containing 130 000 u.I.) after centrifuging was further concentrated to 250 ml., filtered after the addition of charcoal, and excess of aqueous normal lead acetate (20%, w/v) stirred in. The insoluble lead salt was sedimented, washed on the centrifuge with 1% (w/v) lead acetate, suspended in water and decomposed with H2S. The solution (containing 89 000 u.i.), after removal of lead sulphide, was neutralized with aqueous ammonia, treated with charcoal, filtered, concentrated to 25 ml. and filtered from the small amount of deposited solid. The filtrate (containing 84 000 U.I., equivalent to 425 mg. of D-glucaric acid) was heated with 4g. of phenylhydrazine hydrochloride and 1 g. of anhydrous sodium acetate for 5 min. at 1000, decanted hot from gummy material and further heated for 150 min. The cream-coloured crystalline solid (0-63 g.) which separated overnight at 00 had m.p. 203-205°(decomp.) and after recrystallization from aq. 50% (v/v) ethanol the m.p. was 210-211°with no depression on admixture with authentic D-glucaric acid bisphenylhydrazide, m.p. 2100 (decomp.) (Found: C, 55-2; H, 5 9; N, 14-9. Calc. for C18H22N406: C, 55-4; H, 5-7; N, 14.4%). The recrystallized material represented a yield of 63% on coupling with phenylhydrazine, if the inhibitor is assumed to be all Dglucaric acid.
Recoveries on addition of D-glucaric acad and D-glucuronolactone to urine. To 2 1. of pregnancy urine, containing 4600 u.i., was added 1 g. of potassium hydrogen D-glucarate (equivalent to 168 000 u.i.). Assay-of the urine then gave a total of 173 000 u.I.; thus inhibition by the inhibitor in urine and by boiled D-glucarate were fully additive. The urine was then subjected to the same treatment as that given to the urine after ingestion of D-glucuronolactone, giving a final solution (containing 114 000 u.i.) which on condensation with phenylhydrazine hydrochloride yielded D-glucaric acid bisphenylhydrazide, m.p. 204 206°(0-66 g., 61 % yield).
To a further 21. of the same sample of pregnancy urine was added D-glucuronolactone (2 g.). The urine when assayed then showed no change in inhibitory power after acid treatment, but inhibition after alkali treatment was 82 1963 IDENTIFICATION OF-D-GLUCARATE IN URINE increased slightly owing to conversion into D-glucuronic acid, which, unlike its lactone, is a feeble inhibitor of the enzyme (Levvy, 1952) ; Preparation of the lead salt etc., as above, then yielded only a trace of product after condensation with phenylhydrazine hydrochloride. Hydrolysi8 of phenylhydrazine conjugate8 from urine and examinationof the producUt bypaper chromatography. Finelypowdered authentic D-glucaric acid bisphenylhydrazide (500 mg.) was shaken at 200 for 2 hr. with 60 ml. of ethanol-aq. ammonia (sp.gr. 0-88)-water (3:2: 1, by vol.); the residual solid after filtration was shaken with a further similar mixture (60 ml.) for 3 hr., when all was dissolved. The combined solutions were concentrated under reduced pressure and extracted with ether to remove traces of phenylhydrazine. A test of a sample for inhibition of ,Bglucuronidase after acidifying and boiling indicated a recovery of 90 % of D-glucarate from the hydrolysis of the bisphenylhydrazide. The products (15 mg.) from the condensation with phenylhydrazine hydrochloride of concentrates of pregnancy urine and of urine after ingestion of D-glucuronolactone (see above) were likewise shaken with ethanol-aq. ammonia (sp.gr. 0-88)-water. The resultingsolutions, tested as D-glucarate for ,B-glucuronidase inhibition, and on assuming the starting material to be the bisphenylhydrazide, gave recoveries of 80 and 74% respectively for the hydrolysis.
The three hydrolysis products were examined by paper chromatography and gave the following identical patterns.
(a) In propan-l-ol-aq. ammonia (sp.gr. 0-88)-water 
DISCUSSION
From the experimental evidence it may be concluded that D-glucaric acid is a normal constituent of mammalian urine, and the greatly increased excretion of this compound immediately after ingestion of D-glucuronolactone strongly suggests that D-glucarate is a product of D-glucuronic acid metabolism. Mayer (1901) claimed to have isolated D-glucaric acid as its bisphenylhydrazide from the urine of young dogs after subcutaneous injection of D-gluconate, but this work could not be confirmed by Schott (1911) ; Stetten & Stetten (1950) were unable to detect radioactive Dglucarate in the urine after intraperitoneal injection of 14C-labelled D-gluconate into rats. If, as seems probable, D-glucarate is entirely responsible for the acid-potentiated component of ,-glucuronidase inhibition by urine, the human (nonpregnant) excretion is about 10 mg. of D-glucaric acid per day. The concentration of D-glucarate in urine is thus not inconsiderable, but the lack of a unique chemical reaction for the detection of glycaric acids, coupled with their ready transformation into several lactones, makes it difficult to identify and to isolate them from a complex mixture by conventional methods. The method of enzymic assay, depending on the high specificity of boiled D-glucarate as a ,B-glucuronidase inhibitor, has now made possible its estimation in concentrations of the order of 1 /g./ml.
Bacterial decomposition of D-glucuronic acid occurs on standing (Keutel, Schweisfurth & Litos, 1961) , and Kilgore & Starr (1959) found that cellfree extracts of some phytopathic pseudomonads contained an enzyme capable of oxidizing Dglucuronate to a product believed to be D-glucaric acid. However, there was no change in the acidpotentiated P-glucuronidase inhibition by normal human urine after it had stood for 7 weeks at 00, or for 2 weeks at 200 (A. J. Hay, personal communication); moreover, after ingestion of D-glucuronolactone the excretion of D-glucarate in man increased 100-fold and that of uronic acid only 10-fold. It is thus unlikely that the D-glucarate in urine is a product of microbial action; this was confirmed by the identification of a mammalianliver enzyme which in the presence of NAD converted D-glucuronolactone into a product having properties identical with those of the urine inhibitor (Marsh, 1961) . D-Glucuronolactone, but not D-glucuronate, when injected into rats, is partly converted into L-ascorbic acid with retention of the intact carbon chain (Burns & Evans, 1956) , and the production of D-glucaric acid from D-glucuronolactone in mammals, including those able to synthesize the vitamin, implies the existence of a pathway which can compete directly with the production of ascorbic acid. This may account for the much greater increase in excretion of D-glucarate in the guinea pig than in the rat after ingestion of D-glucuronolactone (Table 4) .
The results of ingestion of D-glucuronolactone contrasted sharply with those of ingestion of Dglucuronate or of D-galacturonate, neither of which elevated appreciably the excretion of either the inhibitor or the uronic acid; obviously there is little conversion of D-glucuronate into D-glucuironolactone in the mammalian stomach, despite the favourable acid conditions before absorption. With D-galacturonate the lack of effect may be due to non-absorption through the gut; Werch & Ivy (1941) found that after introduction of D-galacturonic acid into the ileum or colon of dogs, or into the ileum of a human subject, less than 10 % was absorbed after 2 hr. D-Glucuronate may undergo extensive metabolic change during and after a slow absorption process. Packham & Butler (1954) found that negligible [14C]carbon dioxide was respired after intravenous or intraperitoneal injection of uniformly labelled D-glucuronate into rats, and nearly all the radioactivity was excreted in the urine (E. C. Butler, personal communication to Dr G. A. Levvy), whereas, after oral ingestion of the same compound, 58 % of the radioactivity was respired within 8 hr., only 5 % occurred in the urine and a large proportion was retained in the gut (Packham & Butler, 1952) ; (see Levvy, 1956 , for discussion). Oral administration of D-[6-14C]-glucuronic acid to humans also resulted in most of the dose being accounted for in the respired carbon dioxide (Baker, Sauberlich, Wolfskill, Wallace & Dean, 1962) . Administration by injection or ingestion of 14C-labelled D-glucuronolactone (Douglas & King, 1952 , 1953 Packham & Butler, 1954; Baker et al. 1962) showed that this compound is metabolized more rapidly than D-glucuronate, and that contrary to the assumption by some workers (see Douglas & King, 1952 , 1953 Iodide in the thyroid gland is derived from two sources: (a) the blood, and (b) precursors containing organic iodine, thought to be free iodotyrosines, formed during proteolysis of thyroglobulin. Iodide that enters the gland from the circulation has been called the 'first iodide pool'; iodide derived from breakdown products within the gland, the 'second iodide pool ' (Hickey & Brownell, 1954) . The former is discharged from the thyroid by perchlorate and thiocyanate; the latter is not.
The iodide of the thyroid has been determined (as 181I-ion) by a number of workers using different techniques (Wollman & Scow, 1953; Ingbar & Freinkel, 1956; Rosenberg, Athans & Behar, 1960; Wollman, 1962) ; it appears to represent 0*2-0-3 % of the total thyroidal "3"LJ The second iodide pool is larger than the first; its size has been estimated in the rat thyroid (Halmi & Pitt-Rivers, 1962) to be approximately 0-26 % of the thyroidal iodine, a finding that has been confirmed by Nagataki & Ingbar (1963) ; it is nearly 100 times as large as the first pool.
Halmi & Pitt-Rivers (1962) estimated the specific activity of iodide in the second pool at different times up to 24 hr. after single injections of [131I]-iodide and compared the values with the specific activity of thyroglobulin-bound mono-and di-iodotyrosine at corresponding times, determined in a previous study (Pitt-Rivers, 1962) . During the first 8 hr., the specific activity of second-pool iodide rose at a faster rate and reached a maximum sooner than that of any organic iodinated compound. It was therefore suggested that monoiodotyrosine and possibly di-iodotyrosine in thyroglobulin might be heterogeneous with respect to turnover; the fraction turning over more rapidly
